Advertisement

Addition of Pembrolizumab to Trastuzumab and Chemotherapy in Previously Untreated Patients With Advanced HER2-Positive Gastric Adenocarcinoma
Posted: 03/17/2022 | By: Matthew Stenger

Question 1 of 5

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer supported:

Choose 1